Role of lenalidomide in the treatment of peripheral T-cell non-Hodgkin lymphomas

Table 2 Clinical efficacy of lenalidomide single-agent in T-cell lymphomas

Ref.	Patient, n	Study design	Treatment	Histology (number of patients)	ORR	CR rate	Median PFS	Median DOR	Median OS
Ishida et al[44], 2016	26	Multicenter phase II	25 mg continuously until progression or unacceptable toxicity	ATLL (26)	42%	19%	3.8 mo	NR	20.3 mo
Querfeld et al[52], 2014	32	Multicenter phase II	25 mg for 21 d of a 28-d cycle; initial dose was reduced to 10 mg, with the possibility of increasing by 5 mg every cycle, until a maximum of 25 mg, until progression or up to 2 yr for SD or PR, while patients in CR received two additional cycles	Total evaluable (29)	28%	/	8 mo	10 mo	43 mo
				Mycosis fungoides (19)	36.8%
				Sézary syndrome (13)	15.4%
Zinzani et al[56], 2011	10	Phase II, bi-centric	25 mg for 21 d of a 28-d cycle for 4 cycles as induction phase; After the 4th cycle, patients who achieved at least a SD continued for other eight cycles as maintenance	PTCL-NOS (10)	30%	30%	NA	13 mo	NA
Morschhauser et al[51], 2013	54	Multicenter phase II	25 mg on d 1-21 of a 28-d cycle, until progression or unacceptable toxicity, for a maximum of 2 yr	Total evaluable (54)	22%	11%	2.5 mo (4.6 mo in AITL)	3.6 mo	NA
				AITL (26)	31%	15%
				PTCL-NOS (20)	20%	NA
				CTCL (3)	NA	NA
				ALCL (3)	NA	NA
				Cutaneous ALCL (1)	NA	NA
				Extranodal NK/T-cell, nasal type (1)	NA	NA
Toumishey et al[57], 2015	39	Multicenter phase II	25 mg daily on d 1-21 of a 28-d cycle, until progression or unacceptable toxicity	Total evaluable (39)	26%	7.7%	4 mo	13 mo	12 mo
				ALCL (10)	10%	/
				AITL (9)	33%	11.1%
				PTCL-NOS (14)	43%	14.3%
				Other (6)	/	/

AITL: Angioimmunoblastic T-cell lymphoma; ALCL: Anaplastic T-cell lymphoma; ATLL: Adult T-cell lymphoma/leukemia; CTCL: Cutaneous T-cell lymphoma; CR: Complete response; DOR: Duration of response; NA: Not available; NK: Natural killer; NR: Not reached; OS: Overall survival; PR: Partial response; ORR: Overall response rate; PFS: Progression-free survival; PTCL-NOS: Peripheral T-cell lymphomas: Not otherwise specified; SD: Stable disease.